{
    "root": "0096d810-634e-4387-987b-489c513016a4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "toremifene citrate",
    "value": "20250505",
    "ingredients": [
        {
            "name": "toremifene citrate",
            "code": "2498Y783QT"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "COPOVIDONE",
            "code": "D9C330MD8B"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "toremifene citrate tablets estrogen agonist/antagonist indicated treatment metastatic breast cancer postmenopausal women estrogen-receptor positive unknown tumors .",
    "contraindications": "toremifene citrate tablets 60 mg , daily , orally . treatment generally continued disease progression observed .",
    "warningsAndPrecautions": null,
    "adverseReactions": "hypersensitivity ( 4.1 ) qt prolongation , hypokalemia , hypomagnesemia ( 4.2 )",
    "indications_original": "Toremifene citrate tabletsÂ are an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.",
    "contraindications_original": "The dosage of toremifene citrate tablets is 60 mg, once daily, orally. Treatment is generally continued until disease progression is observed.",
    "adverseReactions_original": "Hypersensitivity to the drug ( 4.1 ) QT Prolongation, Hypokalemia, Hypomagnesemia ( 4.2 )"
}